SCHEMBL3222271

SCHEMBL3222271

CN1CCN(c2ccccc2F)c2ccc(-c3ccc(N)nn3)cc2C1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.47
SLC6A3 Q01959 4/20 0.47
SLC6A4 P31645 3/20 0.47
SCN9A Q15858 2/20 0.43
PDK1 Q15118 1/20 0.36
PDK2 Q15119 1/20 0.36
PDK3 Q15120 1/20 0.36
PDK4 Q16654 1/20 0.36
FEN1 P39748 3/20 0.34
HRH4 Q9H3N8 2/20 0.34
ALOX5AP P20292 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
RPS6KA3 P51812 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3231884 0.89 SCN9A (0.41) SLC6A2SLC6A3SLC6A4SCN9AHRH4
SCHEMBL3217112 0.88 SCN9A (0.40) SLC6A2SLC6A3SLC6A4SCN9AHRH4
SCHEMBL3226294 0.87 SLC6A2 (0.47) SLC6A2SLC6A3SLC6A4SCN9APDK1
SCHEMBL3232472 0.86 SCN9A (0.45) SLC6A2SLC6A3SLC6A4SCN9AMEN1
SCHEMBL3227250 0.86 SCN9A (0.39) SLC6A2SLC6A3SLC6A4SCN9AHRH4
SCHEMBL3479668 0.85 SCN9A (0.41) SLC6A2SLC6A3SLC6A4SCN9AMEN1
SCHEMBL3228409 0.85 SLC6A2 (0.49) SLC6A2SLC6A3SLC6A4SCN9APDK1
SCHEMBL3232804 0.85 SLC6A2 (0.45) SLC6A2SLC6A3SLC6A4SCN9AMEN1
SCHEMBL3226960 0.85 SCN9A (0.52) SLC6A2SLC6A3SLC6A4SCN9AHRH4
SCHEMBL3229179 0.84 SCN9A (0.46) SLC6A2SLC6A3SLC6A4SCN9APDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SLC6A2 28/4885SLC6A3 32/4885SLC6A4 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.